Iconovo (ICO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iconovo (ICO) has a cash flow conversion efficiency ratio of -0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.48 Million ≈ $-913.01K USD) by net assets (Skr149.29 Million ≈ $16.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ICO stock market capitalisation for the company's overall valuation and market capitalisation.
Iconovo - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Iconovo's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Iconovo Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iconovo ranked by their cash flow conversion efficiency. Explore cash flow quality index of Iconovo to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indbank Merchant Banking Services Limited
NSE:INDBANK
|
-0.032x |
|
Investcorp Credit Management BDC Inc
NASDAQ:ICMB
|
0.205x |
|
Golden Arrow Resources Corp
V:GRG
|
-0.208x |
|
AVI Global Trust PLC
LSE:AGT
|
0.006x |
|
City Chic Collective Ltd
AU:CCX
|
0.048x |
|
Northeast Electric Development Company Limited
F:NE4H
|
0.009x |
|
Mahube Infrastructure Ltd
JSE:MHB
|
0.009x |
|
Kohinoor Foods Limited
NSE:KOHINOOR
|
-1.314x |
Annual Cash Flow Conversion Efficiency for Iconovo (2016–2025)
The table below shows the annual cash flow conversion efficiency of Iconovo from 2016 to 2025. View Iconovo (ICO) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr117.92 Million ≈ $12.69 Million |
Skr-31.87 Million ≈ $-3.43 Million |
-0.270x | -42.31% |
| 2024-12-31 | Skr129.21 Million ≈ $13.91 Million |
Skr-24.54 Million ≈ $-2.64 Million |
-0.190x | +44.15% |
| 2023-12-31 | Skr113.53 Million ≈ $12.22 Million |
Skr-38.60 Million ≈ $-4.15 Million |
-0.340x | +30.53% |
| 2022-12-31 | Skr89.29 Million ≈ $9.61 Million |
Skr-43.70 Million ≈ $-4.70 Million |
-0.489x | -509.02% |
| 2021-12-31 | Skr137.03 Million ≈ $14.75 Million |
Skr-11.01 Million ≈ $-1.19 Million |
-0.080x | +53.31% |
| 2020-12-31 | Skr92.73 Million ≈ $9.98 Million |
Skr-15.96 Million ≈ $-1.72 Million |
-0.172x | -54.97% |
| 2019-12-31 | Skr108.79 Million ≈ $11.71 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.111x | -599.12% |
| 2018-12-31 | Skr63.99 Million ≈ $6.89 Million |
Skr-1.02 Million ≈ $-109.38K |
-0.016x | +86.88% |
| 2017-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-3.82 Million ≈ $-410.77K |
-0.121x | -117.56% |
| 2016-12-31 | Skr8.73 Million ≈ $939.49K |
Skr6.02 Million ≈ $647.74K |
0.689x | -- |
About Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more